Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · see citing works

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,204 · see citing works

Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene

Mullins, J. J., Peters, J., & Ganten, D. (1990) · Nature · doi:10.1038/344541a0 · Cited by 919 · see citing works

The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies

Hostetter, T. H., Rennke, H. G., & Brenner, B. M. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90490-9 · Cited by 800 · see citing works

Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy.

Zatz, R., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.17.5963 · Cited by 524 · see citing works

Role of angiotensin II in diabetic nephropathy

Leehey, D. J., Singh, A. K., Alavi, N., & Singh, R. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07715.x · Cited by 273 · see citing works

A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR)

Kelly, D. J., Wilkinson‐Berka, J. L., Allen, T. J., Cooper, M. E., & Skinner, S. L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00019.x · Cited by 166 · see citing works

Animal models of spontaneous diabetic kidney disease

Velasquez, M. T., Kimmel, P. L., & Michaelis, O. E. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.11.2199283 · Cited by 118 · see citing works

Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat

Kelly, D. J., Skinner, S. L., Gilbert, R. E., Cox, A. J., Cooper, M. E., & Wilkinson‐Berka, J. L. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00038.x · Cited by 103 · see citing works

Effects of genetic hypertension on diabetic nephropathy in the rat ??? functional and structural characteristics

Cooper, M. E., Allen, T. J., O??Brien, R. C., Macmillan, P. A., Clarke, B. E., Jerums, G., & Doyle, A. E. (1988) · Journal of Hypertension · doi:10.1097/00004872-198812000-00009 · Cited by 95 · see citing works

Pathophysiology of diabetic nephropathy

Cooper, M. E., Gilbert, R. E., & Epstein, M. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90362-6 · Cited by 67 · see citing works

Nephropathy in Model Combining Genetic Hypertension With Experimental Diabetes: Enalapril Versus Hydralazine and Metoprolol Therapy

Cooper, M. E., Allen, T. J., O’Brien, R. C., Papazoglou, D., Clarke, B. E., Jerums, G., & Doyle, A. E. (1990) · Diabetes · doi:10.2337/diab.39.12.1575 · Cited by 58 · see citing works

Experimental diabetic nephropathy: Is it relevant to the human disease

Kelly, D. J., Allen, T. J., & Cooper, M. E. (2000) · Nephrology · doi:10.1046/j.1440-1797.2000.00003.x · Cited by 4 · see citing works

Mechanisms of Diabetic Complications

Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890 · see citing works

Advanced Glycation End Products and Diabetic Complications

Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2014.18.1.1 · Cited by 1,518 · see citing works

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy

Navarro‐González, J. F., Fernández, C. M., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,073 · see citing works

Extracellular Matrix Metabolism in Diabetic Nephropathy

Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 653 · see citing works

Renal Autoregulation in Health and Disease

Carlström, M., Wilcox, C. S., & Arendshorst, W. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00042.2012 · Cited by 485 · see citing works

A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes

Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V., Dean, R. G., Burns, W. C., Tikellis, C., Ritchie, R. H., Twigg, S. M., Cooper, M. E., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000065620.39919.20 · Cited by 449 · see citing works

Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease

MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.048 · Cited by 385 · see citing works

Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences

Panizo, S., Martínez‐Arias, L., Alonso‐Montes, C., Cannata, P., Martín-Carro, B., Martín, J. L. F., Naves‐Díaz, M., Carrillo‐López, N., & Cannata-Andía, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010408 · Cited by 375 · see citing works

Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials

Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 353 · see citing works

Role of Advanced Glycation End Products in Diabetic Nephropathy

Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077413.41276.17 · Cited by 351 · see citing works

Nephrin Expression Is Reduced in Human Diabetic Nephropathy

Doublier, S., Salvidio, G., Lupia, E., Ruotsalainen, V., Verzola, D., Deferrari, G., & Camussi, G. (2003) · Diabetes · doi:10.2337/diabetes.52.4.1023 · Cited by 341 · see citing works

CURCUMIN, THE ACTIVE PRINCIPLE OF TURMERIC (CURCUMA LONGA), AMELIORATES DIABETIC NEPHROPATHY IN RATS

Sharma, S., Kulkarni, S. K., & Chopra, K. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04468.x · Cited by 309 · see citing works

Diabetes-induced Activation of Nuclear Transcriptional Factor in the Retina, and its Inhibition by Antioxidants

Kowluru, R. A., Koppolu, P., Chakrabarti, S., & Chen, S. (2003) · Free Radical Research · doi:10.1080/10715760310001604189 · Cited by 289 · see citing works

QUERCETIN, AN ANTI‐OXIDANT BIOFLAVONOID, ATTENUATES DIABETIC NEPHROPATHY IN RATS

Anjaneyulu, M., & Chopra, K. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.03982.x · Cited by 248 · see citing works

Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*

Mogensen, C. E. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01157.x · Cited by 226 · see citing works

The role of advanced glycation in the pathogenesis of diabetic retinopathy

Stitt, A. W. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00035-2 · Cited by 226 · see citing works

Pathogenesis of diabetic nephropathy

Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00131.x · Cited by 219 · see citing works

Advanced Glycation End Products Induce Tubular Epithelial-Myofibroblast Transition through the RAGE-ERK1/2 MAP Kinase Signaling Pathway

Li, J., Wang, W., Huang, X. R., Oldfield, M. D., Schmidt, A. M., Cooper, M. E., & Lan, H. Y. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63225-7 · Cited by 217 · see citing works

Epigenetics

Cooper, M. E., & El‐Osta, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.223552 · Cited by 211 · see citing works

The role of protein kinase C activation in diabetic nephropathy

Noh, H., & King, G. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002386 · Cited by 212 · see citing works

Diabetic Nephropathy: a Tangled Web to Unweave

Magee, C., Grieve, D., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 192 · see citing works

Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies

Ricciardi, C. A., & Gnudi, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154890 · Cited by 197 · see citing works

Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase Cβ–Null Mice

Ohshiro, Y., Ronald, C. W., Yasuda, Y., Hiraoka‐Yamamoto, J., Clermont, A. C., Isshiki, K., Yagi, K., Arikawa, E., Kern, T. S., & King, G. L. (2006) · Diabetes · doi:10.2337/db06-0895 · Cited by 189 · see citing works

Diabetic Nephropathy: Where Hemodynamics Meets Metabolism

Forbes, J. M., Fukami, K., & Cooper, M. E. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-949721 · Cited by 183 · see citing works

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 182 · see citing works

Resveratrol, a Polyphenolic Phytoalexin, Attenuates Diabetic Nephropathy in Rats

Sharma, S., Anjaneyulu, M., Kulkarni, S., & Chopra, K. (2005) · Pharmacology · doi:10.1159/000089720 · Cited by 177 · see citing works

The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy

Zhang, C., Xiao, C., Wang, P., Xu, W., Zhang, A., Li, Q., & Xu, X. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.02.007 · Cited by 166 · see citing works

Increased plasma urotensin II levels in patients with diabetes mellitus

Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S., & Murakami, O. (2003) · Clinical Science · doi:10.1042/cs20020271 · Cited by 160 · see citing works

Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms

Tonna, S. J., El‐Osta, A., Cooper, M. E., & Tikellis, C. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.55 · Cited by 152 · see citing works

Interactions between Angiotensin II and NF-κB–Dependent Pathways in Modulating Macrophage Infiltration in Experimental Diabetic Nephropathy

Lee, F., Cao, Z., Long, D. M., Panagiotopoulos, S., Jerums, G., Cooper, M. E., & Forbes, J. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000135055.61833.a8 · Cited by 150 · see citing works

Advanced glycation end products and diabetic complications

Stitt, A. W., Jenkins, A. J., & Cooper, M. E. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.9.1205 · Cited by 150 · see citing works

Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy

Barutta, F., Piscitelli, F., Pinach, S., Bruno, G., Gambino, R., Rastaldi, M. P., Salvidio, G., Marzo, V. D., Perin, P. C., & Gruden, G. (2011) · Diabetes · doi:10.2337/db10-1809 · Cited by 145 · see citing works

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.12.002 · Cited by 145 · see citing works

Renal Connective Tissue Growth Factor Induction in Experimental Diabetes Is Prevented by Aminoguanidine

Twigg, S. M., Cao, Z., McLennan, S., Burns, W. C., Brammar, G. C., Forbes, J. M., & Cooper, M. E. (2002) · Endocrinology · doi:10.1210/en.2002-220619 · Cited by 143 · see citing works

Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes

Brouwers, O., Niessen, P. M. G., Miyata, T., Østergaard, J. A., Flyvbjerg, A., Peutz‐Kootstra, C. J., Sieber, J., Mundel, P. H., Brownlee, M., Janssen, B. J., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-3088-5 · Cited by 139 · see citing works

Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney

Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K. A. M., Cooper, M. E., & Forbes, J. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010013 · Cited by 135 · see citing works

Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy

Adelusi, T. I., Du, L., Meng, H., Zhou, X., Qian, X., Chowdhury, A., Sun, Y., Lü, Q., & Yin, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109732 · Cited by 133 · see citing works

Early oxidative stress in the diabetic kidney: effect of DL-α-lipoic acid

Obrosova, I. G., Fathallah, L., Liu, E., & Nourooz‐Zadeh, J. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01195-4 · Cited by 129 · see citing works

Activation of ERK in renal fibrosis after unilateral ureteral obstruction: Modulation by antioxidants

Pat, B., Yang, T., Kong, C., Watters, D. J., Johnson, D. W., & Gobe, G. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00157.x · Cited by 128 · see citing works

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy

Koch, A., Kuhlmann, A., M�nter, K., Ritz, E., Amann, K., Gross, M.-L., Elshakmak, A., & Sz�b�, A. (2003) · Diabetologia · doi:10.1007/s00125-003-1106-8 · Cited by 126 · see citing works

Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?

Coughlan, M. T., Thallas-Bonke, V., Pete, J., Long, D. M., Gasser, A., Tong, D. C. K., Arnstein, M., Thorpe, S. R., Cooper, M. E., & Forbes, J. M. (2007) · Endocrinology · doi:10.1210/en.2006-1300 · Cited by 124 · see citing works

Diabetic nephropathy: Important pathophysiologic mechanisms

Soldatos, G., & Cooper, M. E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.042 · Cited by 123 · see citing works

New insights: A role forO-GlcNAcylation in diabetic complications

Peterson, S. B., & Hart, G. W. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1135102 · Cited by 123 · see citing works

Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes

Tarabra, E., Giunti, S., Barutta, F., Salvidio, G., Burt, D. J., Deferrari, G., Gambino, R., Vergola, D., Pinach, S., Perin, P. C., et al. (2009) · Diabetes · doi:10.2337/db08-0895 · Cited by 121 · see citing works

Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice

Lassila, M., Jandeleit-Dahm, K. A. M., Seah, K. K., Smith, C. M., Calkin, A. C., Allen, T. J., & Cooper, M. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050392 · Cited by 117 · see citing works

Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?

Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 111 · see citing works

Mechanical Forces in Diabetic Kidney Disease

Gnudi, L., Thomas, S. M., & Viberti, G. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121362 · Cited by 113 · see citing works

Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy

Gomes, I. B., Porto, M. L., Santos, M. C. L. F. S., Campagnaro, B. P., Pereira, T. M., Meyrelles, S. S., & Vasquez, E. C. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-184 · Cited by 109 · see citing works

Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation

Kim, M. N., Moon, J. H., & Cho, Y. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14503 · Cited by 110 · see citing works

The impact of hyperfiltration on the diabetic kidney

Premaratne, E., Verma, S. K., Ekinci, E. I., Theverkalam, G., Jerums, G., & MacIsaac, R. J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.003 · Cited by 108 · see citing works

Hypertension and diabetes

Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00014 · Cited by 106 · see citing works

Role of T Cells in Type 2 Diabetic Nephropathy

Wu, C., Sytwu, H., Lu, K., & Lin, Y. (2011) · Experimental Diabetes Research · doi:10.1155/2011/514738 · Cited by 113 · see citing works

ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat

Wilkinson‐Berka, J. L., Kelly, D. J., Koerner, S. M., Jaworski, K., Davis, B., Thallas, V., & Cooper, M. E. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3283 · Cited by 105 · see citing works

Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy

Xie, X., Peng, J., Chang, X., Huang, K., Huang, J., Wang, S., Shen, X., Liu, P., & Huang, H. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.007 · Cited by 102 · see citing works

Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice

Xiao, X., Ma, B., Dong, B., Zhao, P., Tai, N., Chen, L., Wong, F. S., & Li, W. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2008.12.003 · Cited by 99 · see citing works

Role of advanced glycation end products and insulin resistance in diabetic nephropathy

Parwani, K., & Mandal, P. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1797106 · Cited by 97 · see citing works

Potential New Therapeutic Agents for Diabetic Kidney Disease

Turgut, F. H., & Bolton, W. K. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.11.021 · Cited by 96 · see citing works

Deletion of Protein Kinase C-β Isoform In Vivo Reduces Renal Hypertrophy but Not Albuminuria in the Streptozotocin-Induced Diabetic Mouse Model

Meier, M., Park, J.-K., Overheu, D., Kirsch, T., Lindschau, C., Gueler, F., Leitges, M., Menne, J., & Haller, H. G. (2007) · Diabetes · doi:10.2337/db06-0891 · Cited by 96 · see citing works

Diabetes‐induced overexpression of endothelin‐1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP‐ribose) polymerase activation

Minchenko, О. H., Stevens, M. J., White, L., Abatan, O. I., Komjáti, K., Pachter, P., Szabó, C., & Obrosova, I. G. (2003) · The FASEB Journal · doi:10.1096/fj.03-0013fje · Cited by 96 · see citing works

Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse

Chen, H., Li, J., Jiao, L., Petersen, R. B., Li, J., Peng, A., Zheng, L., & Huang, K. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.266411 · Cited by 93 · see citing works

Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy

Wu, C., Chen, J.-S., Lu, K., Chen, C., Lin, S., Chu, P., Sytwu, H., & Lin, Y. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.01.036 · Cited by 92 · see citing works

Research progress in signalling pathway in diabetic nephropathy

Ni, W., Tang, L., & Wei, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2568 · Cited by 90 · see citing works

Heat-processed Panax ginseng and diabetic renal damage: active components and action mechanism

Kang, K. S., Ham, J., Kim, Y., Park, J. H., Cho, E. J., & Yamabe, N. (2013) · Journal of Ginseng Research · doi:10.5142/jgr.2013.37.379 · Cited by 89 · see citing works

Diabetes and Hypertension: Epidemiology of the Relationship and Pathophysiology of Factors Associated With These Comorbid Conditions

Schutta, M. H. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.06368.x · Cited by 89 · see citing works

Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice

Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., & Kawabe, Y. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12269 · Cited by 88 · see citing works

GLUT-1 Overexpression

Gnudi, L., Viberti, G., Raij, L. R., Rodriguez, V., Burt, D. J., Cortés, P., Hartley, B., Thomas, S., Maestrini, S., & Gruden, G. (2003) · Hypertension · doi:10.1161/01.hyp.0000075949.19968.ef · Cited by 86 · see citing works

Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells

Giunti, S., Tesch, G. H., Pinach, S., Burt, D. J., Cooper, M. E., Cavallo‐Perin, P., Camussi, G., & Gruden, G. (2007) · Diabetologia · doi:10.1007/s00125-007-0837-3 · Cited by 85 · see citing works

Decreased Expression of Pigment Epithelium-Derived Factor Is Involved in the Pathogenesis of Diabetic Nephropathy

Wang, J. J., Zhang, S. X., Lu, K., Chen, Y., Mott, R., Sato, S., & Ma, J. (2005) · Diabetes · doi:10.2337/diabetes.54.1.243 · Cited by 85 · see citing works

Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease

Jerums, G., Panagiotopoulos, S., Forbes, J. M., Osicka, T. M., & Cooper, M. E. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.017 · Cited by 85 · see citing works

The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose–fat diet and streptozotocin-induced diabetic nephropathy rats

Zhang, M.-H., Feng, L., Zhu, M., Gu, J., Jiang, J., Cheng, X., Ding, S., Wu, C., & Jia, X. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.11.015 · Cited by 84 · see citing works

Omega-3 fatty acid rich diet prevents diabetic renal disease

Garman, J. H., Mulroney, S. E., Manigrasso, M. B., Flynn, E., & Maric, C. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90326.2008 · Cited by 84 · see citing works

Apelin/APJ system in inflammation

Wang, X., Zhang, L., Li, P., Zheng, Y., Yang, Y., & Ji, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108822 · Cited by 83 · see citing works

Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs

Lee, E. J., Kim, J. Y., & Oh, S. H. (2016) · Scientific Reports · doi:10.1038/srep27848 · Cited by 82 · see citing works

Protective Effects of Astragalus Saponin I on Early Stage of Diabetic Nephropathy in Rats

Yin, X., Zhang, Y., Wu, H., Zhu, X., Zheng, X., Jiang, S., Zhuo, H., Shen, J., Li, L., & Qiu, J. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0030597 · Cited by 81 · see citing works

Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II–Generating Pathway in Diabetic Complications

Koka, V., Wang, W., Huang, X. R., Kim‐Mitsuyama, S., Truong, L. D., & Lan, H. Y. (2006) · Circulation · doi:10.1161/circulationaha.105.575589 · Cited by 81 · see citing works

Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus

Couture, R., & Girolami, J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.045 · Cited by 79 · see citing works

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

Abatan, O. I., Charniauskaya, T., Stevens, M., Obrosova, I. G., Pacher, P., Li, F., Szab�, C., & Southan, G. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1356-0 · Cited by 79 · see citing works

Wogonin Ameliorates Renal Inflammation and Fibrosis by Inhibiting NF-κB and TGF-β1/Smad3 Signaling Pathways in Diabetic Nephropathy

Zheng, Z., Zhu, W., Lei, L., Liu, X., & Wu, Y. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s274256 · Cited by 78 · see citing works

Protective effects of chronic melatonin treatment against renal injury in streptozotocin‐induced diabetic rats

Çam, M., Yavuz, Ö., Güven, A., Ercan, F., Bukan, N. C., & Üstündag, N. (2003) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2003.00082.x · Cited by 77 · see citing works

Impact of kinins in the treatment of cardiovascular diseases

Regoli, D. C., Plante, G. E., & Gobeil, F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.002 · Cited by 77 · see citing works

TNF-αand Microalbuminuria in Patients with Type 2 Diabetes Mellitus

Lampropoulou, I.-T., Stangou, M. J., Papagianni, A. A., Didangelos, T., Iliadis, F. S., & Efstratiadis, G. (2014) · Journal of Diabetes Research · doi:10.1155/2014/394206 · Cited by 76 · see citing works

Therapeutic potential of 20(S)-ginsenoside Rg3 against streptozotocin-induced diabetic renal damage in rats

Kang, K. S., Yamabe, N., Kim, H., Park, J. H., & Yokozawa, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.077 · Cited by 74 · see citing works

Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli ofdb/dbdiabetic mice

Barati, M. T., Merchant, M. L., Kain, A. B., Jevans, A. W., McLeish, K. R., & Klein, J. B. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00411.2006 · Cited by 74 · see citing works

Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Zhang, H., Saha, J., Byun, J., Schin, M., Lorenz, M. A., Kennedy, R. T., Kretzler, M., Feldman, E. L., Pennathur, S., & Brosius, F. C. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90208.2008 · Cited by 74 · see citing works

Effects of grape seed proanthocyanidin extract on oxidative stress induced by diabetes in rat kidney.

Mansouri, E., Panahi, M., Ghaffari, M. A., & Ghorbani, A. (2011) · Europe PMC (PubMed Central) · Cited by 73 · see citing works

A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications

Babel, R. A., & Dandekar, M. P. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666201103143818 · Cited by 76 · see citing works

Effect of Irbesartan on the Antioxidant Defence System and Nitric Oxide Release in Diabetic Rat Kidney

Anjaneyulu, M., & Chopra, K. (2004) · American Journal of Nephrology · doi:10.1159/000080722 · Cited by 70 · see citing works

Potential role of active vitamin D in retarding the progression of chronic kidney disease

Tian, J., Liu, Y., Williams, L. A., & de Zeeuw, D. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl595 · Cited by 70 · see citing works

Cytokines in diabetic nephropathy

Wu, C., Sytwu, H., & Lin, Y. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00014-5 · Cited by 67 · see citing works

The Attenuation of Moutan Cortex on Oxidative Stress for Renal Injury in AGEs-Induced Mesangial Cell Dysfunction and Streptozotocin-Induced Diabetic Nephropathy Rats

Zhang, M., Feng, L., Gu, J., Ma, L., Qin, D., Wu, C., & Jia, X. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/463815 · Cited by 67 · see citing works

Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy

Rincon-Choles, H., Kasinath, B. S., Gorin, Y. C., & Abboud, H. E. (2002) · Kidney International · doi:10.1046/j.1523-1755.62.s82.3.x · Cited by 67 · see citing works

Apelin/APJ system: A novel potential therapy target for kidney disease

Huang, Z., Wu, L., & Chen, L. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26144 · Cited by 66 · see citing works

Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin

Zhang, Y., Wang, Y., Lou, Y., Luo, M., Lu, Y., Li, Z., Wang, Y., & Miao, L. (2018) · Peptides · doi:10.1016/j.peptides.2018.09.006 · Cited by 66 · see citing works

Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat

Davis, B. J., Forbes, J. M., Thomas, M. C., Jerums, G., Burns, W. C., Kawachi, H., Allen, T. J., & Cooper, M. E. (2004) · Diabetologia · doi:10.1007/s00125-003-1256-8 · Cited by 65 · see citing works

Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease

Patel, D. M., Bose, M., & Cooper, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062218 · Cited by 65 · see citing works

Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression

Matsui, T., Yamagishi, S., Takeuchi, M., Ueda, S., Fukami, K., & Okuda, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.07.004 · Cited by 64 · see citing works

VEGF gene polymorphism association with diabetic neuropathy

Tavakkoly‐Bazzaz, J., Amoli, M. M., Pravica, V., Chandrasecaran, R., Boulton, A. J. M., Larijani, B. A., & Hutchinson, I. V. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0013-6 · Cited by 64 · see citing works

Nordihydroguairetic Acid, a Lignin, Prevents Oxidative Stress and the Development of Diabetic Nephropathy in Rats

Anjaneyulu, M., & Chopra, K. (2004) · Pharmacology · doi:10.1159/000078631 · Cited by 64 · see citing works

Dual Inhibition of Classical Protein Kinase C-α and Protein Kinase C-β Isoforms Protects Against Experimental Murine Diabetic Nephropathy

Menne, J., Shushakova, N., Bartels, J., Kiyan, Y., Laudeley, R., Haller, H. G., Park, J.-K., & Meier, M. (2013) · Diabetes · doi:10.2337/db12-0534 · Cited by 63 · see citing works

Heat shock protein expression in diabetic nephropathy

Barutta, F., Pinach, S., Giunti, S., Vittone, F., Forbes, J. M., Chiarle, R., Arnstein, M., Perin, P. C., Camussi, G., Cooper, M. E., et al. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90234.2008 · Cited by 63 · see citing works

Diabetic Nephropathy: Where Hemodynamics Meets Metabolism

Forbes, J. M., Fukami, K., & Cooper, M. E. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-949721 · Cited by 183 · see citing works

Pathogenesis, prevention, and treatment of diabetic nephropathy

Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 555 · see citing works

Pathogenesis of diabetic nephropathy

Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00131.x · Cited by 219 · see citing works

Novel Therapeutic Targets for Diabetic Nephropathy

Fukami, K., Yamagishi, S., Ueda, S., & Okuda, S. (2007) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153007780832118 · Cited by 23 · see citing works

Pathogenesis of Diabetic Nephropathy: Hemodynamic Alterations/Renin Angiotensin System

Alper, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_4